The median survival for patients with metastatic bladder cancer is increasing, possibly due to increasing use of immunotherapy.
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief.
Patients undergoing radical cystectomy for bladder cancer have an increased risk of thromboembolic events that may persist for months after surgery.
Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.
Aortic calcification may lead to arterial degradation that increases the risk for acute kidney injury, according to investigators.
Gemcitabine plus docetaxel “may serve as a reasonable alternative first-line therapy for patients with high-risk NMIBC during the ongoing BCG shortage,” according to researchers.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
A protocol for eliminating routine opioid prescription after major urologic cancer surgery was both safe and successful, according to researchers.
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
A high pretreatment neutrophil-to-lymphocyte ratio is associated with worse outcomes in patients with muscle-invasive bladder cancer, a study suggests.
A survey of US urologic oncologists suggests that reproductive organ-sparing and nerve-sparing radical cystectomy may be underused in women with bladder cancer.
Incidence and mortality rates for major genitourinary cancers differ according to sex, race/ethnicity, and geographic region.
A systematic review evaluated current and investigational intravesical and systemic therapies for NMIBC after BCG failure, including chemotherapy, immunotherapy, combination therapy, hyperthermia, and novel biologic agents.
The FDA has approved the gene therapy Adstiladrin (nadofaragene firadenovec-vncg) to treat high-risk, non-muscle-invasive bladder cancer.
Pipes, cigars, e-cigarettes, and marijuana were not tied to recurrence risk.
A single-institution study revealed that 37% of patients who underwent radical cystectomy experienced at least 1 additional intervention.
The decision to withdraw the indication was made based on findings from the phase 3 IMvigor130 trial.
Recurrence of bladder cancer after radical cystectomy can occur up to 4 years after surgery, a study suggests.
Study results suggest that tumor debulking does not benefit patients undergoing radical cystectomy.